Juvenile idiopathic arthritis–associated uveitis (JIAU) is the most common systemic disease-associated uveitis in childhood and remains an important cause of ocular morbidity and vision loss.1,2 Despite its name, JIAU should not necessarily be considered a disease confined to childhood. Many patients experience ocular inflammation that persists or recurs into adulthood, while others enter adulthood with cumulative structural complications resulting from years of inflammation and corticosteroid exposure. Thus, ophthalmologists may encounter adult patients with active uveitis, treatment-dependent remission, or inactive disease complicated by cataract, glaucoma, macular edema, band keratopathy, or hypotony.3-7 Understanding this evolving adult phenotype is increasingly important because advances in screening and systemic immunomodulatory therapy allow more children with JIAU to reach adulthood with preserved vision.
Characteristics of JIAU in Adults
Juvenile idiopathic arthritis is the most common rheumatologic disease of childhood and can remain active well beyond the pediatric years. Long-term studies demonstrate that a substantial proportion of patients continue to experience active disease, pain, physical disability, and impaired health-related quality of life in adulthood.8,9 Importantly, remission of arthritis does not necessarily parallel remission of uveitis.
Uveitis develops in approximately 10% to 20% of children with JIA.1,2,10 The classic phenotype is a chronic, bilateral, nongranulomatous anterior uveitis that is frequently asymptomatic. Younger age at arthritis onset, antinuclear antibody (ANA) positivity, female sex, and oligoarticular JIA are recognized risk factors.2,10 In contrast, patients with enthesitis-related arthritis or HLA-B27–associated disease more commonly develop an acute, symptomatic anterior uveitis characterized by pain, photophobia, and redness.10
Although JIAU is generally diagnosed during childhood, reaching adulthood does not guarantee ocular remission. Oray et al retrospectively evaluated 77 adults with JIAU and found that 52% had ongoing inflammation at their final visit.3 Posterior synechiae and hypotony at presentation were independent predictors of persistent inflammation. Other adult cohorts have similarly demonstrated persistent or recurrent inflammation well beyond childhood.4,5
More recent data specifically examining patients at transition to adult care reinforce this substantial disease burden. Raymond et al reported that approximately half of patients had active uveitis at transition, 46% had developed ocular complications—including cataract in 24% and glaucoma in 20%—and 53% continued to receive biologic disease-modifying antirheumatic drugs (DMARDs).6 These findings challenge the assumption that JIAU routinely “burns out” with age.
Long-Term Ocular Complications and Visual Prognosis
The adult phenotype of JIAU reflects not only current inflammatory activity but also the cumulative effects of inflammation and treatment throughout childhood. Common complications include posterior synechiae, band keratopathy, cataract, ocular hypertension and glaucoma, macular edema, epiretinal membrane, hypotony, and optic nerve damage.1-5
In the adult cohort reported by Oray et al, 72% of eyes had at least 1 ocular complication, including band keratopathy in 42%, cataract in 25%, posterior synechiae in 22%, maculopathy in 22%, ocular hypertension in 13%, and hypotony in 5%.3 Twenty-eight percent of eyes had visual acuity of 20/50 or worse, whereas 15% had visual acuity of 20/200 or worse.
The population-based Nordic JIA cohort provides additional insight into the long-term disease burden. At 18 years after JIA onset, uveitis remained an important cause of ocular morbidity, emphasizing that complications continue to accumulate long after the initial pediatric diagnosis.7
A recent systematic review and meta-analysis provides an even broader perspective. Across 22 studies encompassing 2,208 patients with long-term JIAU, the pooled incidence of severe visual impairment was 16.6% after approximately 18 years of follow-up. Cataract was the most frequent complication, occurring in an estimated 44.3%, followed by glaucoma, posterior synechiae, band keratopathy, and hypotony.11 Importantly, complication rates were numerically lower in cohorts with greater exposure to biologic therapy, suggesting that contemporary treatment may be changing the natural history of JIAU, although long-term prospective data are still needed.
These findings highlight an important distinction in adulthood: Absence of active inflammation does not necessarily mean absence of ocular disease. A patient may have completely quiet anterior chambers while experiencing permanent visual consequences of childhood inflammation, including amblyopia, glaucomatous optic neuropathy, chronic macular edema, or complications of previous ocular surgery.
Systemic Immunomodulatory Therapy: Does Treatment End in Adulthood?
Topical corticosteroids remain the initial treatment for anterior uveitis; however, prolonged corticosteroid dependence increases the risks of cataract and glaucoma. Systemic steroid-sparing immunomodulatory therapy is therefore recommended when inflammation cannot be adequately controlled with an acceptable topical corticosteroid burden. Methotrexate remains the most commonly used conventional DMARD, although monoclonal tumor necrosis factor (TNF) inhibitors—particularly adalimumab and infliximab—have transformed the management of refractory or sight-threatening disease.10,12
One of the most important practical issues during transition is determining whether systemic therapy can be discontinued. Young adults may have clinically inactive arthritis and no ocular symptoms and may understandably question the need for continued immunosuppression. However, ocular and articular disease activity can be discordant, and apparent ocular remission may represent successful pharmacologic suppression rather than true treatment-free remission.5,6
The ADJUST randomized clinical trial provides important evidence regarding this issue. Among patients with controlled JIAU receiving adalimumab, treatment failure occurred in 68% of patients randomized to placebo (adalimumab withdrawal) compared with 14% of those who continued adalimumab.13 The median time to treatment failure following withdrawal was 119 days. Importantly, after restarting adalimumab, the median time required to reestablish sustained inflammatory control was 105 days.13
These findings emphasize that discontinuation of biologic therapy is not without risk and should be approached cautiously. Current guidelines recommend that uveitis be well controlled for at least 2 years before attempting to taper systemic therapy, but reliable biomarkers capable of identifying patients who will maintain treatment-free remission are lacking.10 For the adult ophthalmologist, a detailed history of previous ocular activity and treatment is therefore critical before supporting reduction or discontinuation of systemic therapy.
Cataract and Glaucoma: Managing the Legacy of Childhood Inflammation
Cataract and glaucoma are among the most important causes of long-term visual morbidity in adults with JIAU. Cataract may result from chronic inflammation, corticosteroid exposure, or both. Cataract surgery can be challenging because of posterior synechiae, small pupils, pupillary membranes, previous glaucoma surgery, and increased risks of postoperative inflammation and macular edema.14
Modern cataract surgery and improved inflammatory control have substantially changed the prognosis. Whenever possible, inflammation should be well controlled for at least 3 months before surgery, systemic immunomodulatory therapy should generally be maintained, and perioperative anti-inflammatory therapy should be individualized according to previous disease severity.14,15 Intraocular lens (IOL) implantation is now routinely considered in appropriately controlled JIAU, representing an important change from earlier eras when aphakia was frequently preferred because of concerns regarding severe postoperative inflammation. Contemporary studies using foldable hydrophobic acrylic IOLs in appropriately selected, immunosuppressed patients have demonstrated favorable visual outcomes.15
Glaucoma presents a different challenge. Elevated intraocular pressure (IOP) may result from chronic trabecular inflammation, peripheral anterior synechiae, corticosteroid response, or a combination of these mechanisms. Medical therapy may be insufficient, and surgical intervention may ultimately be required.16 Options include angle surgery, glaucoma drainage devices, and, in selected cases, trabeculectomy. Successful glaucoma management requires simultaneous control of inflammation and IOP. Close collaboration between uveitis and glaucoma specialists is particularly valuable in these complex eyes.
Recent Advances: Is the Adult Phenotype Changing?
The prognosis of JIAU has improved considerably over recent decades. Earlier diagnosis through standardized ophthalmic screening, earlier introduction of steroid-sparing immunomodulatory therapy, and widespread use of biologic agents have reduced exposure to uncontrolled inflammation and chronic corticosteroids.7,10,12
The 2019 American College of Rheumatology/Arthritis Foundation guideline represented an important shift toward earlier systemic control of ocular inflammation.10 Systemic therapy should be considered when children need 1 to 2 drops per day of prednisolone acetate 1% to maintain control, and severe active or sight-threatening disease may warrant early combination treatment with methotrexate and an anti-TNF agent rather than prolonged sequential escalation.10 The emphasis has increasingly shifted from treating individual flares to preventing cumulative ocular damage.
The biologic era may therefore be producing a new generation of adults with JIAU. Historical adult cohorts include patients treated before methotrexate and anti-TNF therapy became widely used and consequently carry substantial cataract, glaucoma, hypotony, and visual morbidity.3-5 In contrast, the recent long-term meta-analysis found numerically lower estimates of ocular complications in cohorts in which more than 50% of patients had received biologic therapy.11
Whether early biologic therapy truly modifies the lifetime natural history of JIAU remains unknown. Children treated aggressively today may enter adulthood with better preserved ocular structures and vision than previous generations, although many may remain dependent on systemic therapy. Long-term prospective studies and registries will be needed to determine whether improved inflammatory control during childhood translates into sustained visual benefit decades later.
Transition to Adult Care: Practical Considerations for Ophthalmologists
Transition represents a particularly vulnerable period. Pediatric rheumatology and ophthalmology teams may have followed patients closely for many years, but this established multidisciplinary structure can be disrupted when patients enter adult care. Because JIAU can remain asymptomatic even when active, gaps in ophthalmic follow-up may allow significant inflammation to recur unnoticed.6
The adult ophthalmologist should therefore obtain more than a simple history of “JIA with previous uveitis.” Whenever possible, the transition record should include age at onset of arthritis and uveitis, previous severity and frequency of ocular flares, history of macular edema or hypotony, cumulative ocular complications and surgeries, previous systemic agents and reasons for discontinuation, biologic failures, corticosteroid dependence, and—critically—the duration of true ocular quiescence.
Continued communication with rheumatology remains essential even when arthritis is inactive. Decisions regarding tapering or discontinuing systemic therapy should incorporate ocular history rather than being based solely on musculoskeletal remission. Similarly, patients with glaucoma, cataract, or complex previous surgery may benefit from coordinated care among uveitis, glaucoma, retina, and anterior-segment specialists.
Finally, adult patients should understand that absence of symptoms does not reliably indicate absence of inflammation. Educating patients about the need for continued ophthalmic surveillance may be one of the most important components of successful transition.
Conclusion
JIA-associated uveitis does not necessarily end when childhood does. Many patients reach adulthood with persistent or recurrent inflammation, continued dependence on systemic immunomodulatory therapy, or cumulative ocular complications from disease that began years earlier. Cataract and glaucoma remain major causes of visual morbidity, and successful management requires control of both current inflammation and the structural consequences of previous disease.
At the same time, the adult phenotype of JIAU appears to be changing. Earlier screening, steroid-sparing immunomodulatory therapy, and biologic agents have improved disease control and may reduce long-term ocular damage. Whether children treated aggressively in the modern biologic era will experience substantially better lifetime visual outcomes remains an important unanswered question.
For ophthalmologists caring for these patients in adulthood, the key message is simple: Transition from pediatric to adult care should not be interpreted as transition from active disease to cured disease. Continued ophthalmic surveillance, thoughtful decisions regarding systemic therapy, aggressive management of ocular complications, and sustained collaboration with rheumatology remain essential to preserving vision throughout adulthood. RP
Reference
1. Thorne JE, Woreta F, Kedhar SR, Dunn JP, Jabs DA. Juvenile idiopathic arthritis- associated uveitis: incidence of ocular complications and visual acuity loss. Am J Ophthalmol. 2007;143(5):840-846. doi:10.1016/j.ajo.2007.01.033
2. Vitale AT, Graham E, de Boer JH. Juvenile idiopathic arthritis-associated uveitis: clinical features and complications, risk factors for severe course, and visual outcome. Ocul Immunol Inflamm. 2013;21(6):478-485. doi:10.3109/09273948.2013.815785
3. Oray M, Khachatryan N, Ebrahimiadib N, Abu Samra K, Lee S, Foster CS. Ocular morbidities of juvenile idiopathic arthritis-associated uveitis in adulthood: results from a tertiary center study. Graefes Arch Clin Exp Ophthalmol. 2016;254(9):1841-1849. doi:10.1007/s00417-016-3340-z
4. Kolomeyer AM, Crane ES, Tu Y, Liu D, Chu DS. Adult patients with uveitis associated with juvenile idiopathic arthritis: a retrospective review. Can J Ophthalmol. 2017;52(5):458-462. doi:10.1016/j.jcjo.2017.01.011
5. Paroli MP, Abbouda A, Albanese G, et al. Persistence of juvenile idiopathic arthritis-associated uveitis in adulthood: a retrospective study. J Clin Med. 2022;11(9):2471. doi:10.3390/jcm11092471
6. Raymond A, Combier A, Hecquet S, et al. Characteristics of JIA-associated uveitis at the age of transition. Pediatr Rheumatol Online J. 2026;24(1):32. doi:10.1186/s12969-026-01217-4
7. Rypdal V, Glerup M, Songstad NT, et al; Nordic Study Group of Pediatric Rheumatology. Uveitis in juvenile idiopathic arthritis: 18-year outcome in the population-based Nordic cohort study. Ophthalmology. 2021;128(4):598-608. doi:10.1016/j.ophtha.2020.08.024
8. Glerup M, Rypdal V, Arnstad ED, et al. Long-term outcomes in juvenile idiopathic arthritis: eighteen years of follow-up in the population-based Nordic Juvenile Idiopathic Arthritis Cohort. Arthritis Care Res (Hoboken). 2020;72(4):507-516. doi:10.1002/acr.23853
9. Tollisen A, Selvaag AM, Aulie HA, et al. Physical functioning, pain, and health-related quality of life in adults with juvenile idiopathic arthritis: a longitudinal 30-year follow-up study. Arthritis Care Res (Hoboken). 2018;70(5):741-749. doi:10.1002/acr.23327
10. Angeles-Han ST, Ringold S, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis-associated uveitis. Arthritis Care Res (Hoboken). 2019;71(6):703-716. doi:10.1002/acr.23871
11. Scagnellato L, Cozzi G, Lorenzin M, et al. Long-term outcomes of JIA-associated uveitis: a systematic review and meta-analysis. RMD Open. 2025;11(4):e006071. doi:10.1136/rmdopen-2025-006071
12. Clarke SL, Maghsoudlou P, Guly CM, Dick AD, Ramanan AV. The management of adult and paediatric uveitis for rheumatologists. Nat Rev Rheumatol. 2024;20(12):795-808. doi:10.1038/s41584-024-01181-x
13. Acharya NR, Ramanan AV, Coyne AB, et al; ADJUST Study Group. Stopping of adalimumab in juvenile idiopathic arthritis-associated uveitis (ADJUST): a multicentre, double-masked, randomised controlled trial. Lancet. 2025;405(10475):303-313. doi:10.1016/S0140-6736(24)02468-1
14. Clarke SL, Sen ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis. Pediatr Rheumatol Online J. 2016;14(1):27. doi:10.1186/s12969-016-0088-2
15. Grajewski RS, Zurek-Imhoff B, Roesel M, Heinz C, Heiligenhaus A. Favourable outcome after cataract surgery with IOL implantation in uveitis associated with juvenile idiopathic arthritis. Acta Ophthalmol. 2012;90(7):657-662. doi:10.1111/j.1755-3768.2011.02110.x
16. Barresi C, Baldo F, Menean M, et al. Juvenile idiopathic arthritis and associated uveitis: a review of pathogenesis, diagnosis, and management. Saudi J Ophthalmol. 2025;39(1):31-40. doi:10.4103/sjopt.sjopt_153_24